A Retrospective Study of Lip Hemangiomas: Curative Effect of Oral Propranolol Combined with Topical Sclerotherapy.

Publisher: Wiley Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE

Publication: 2024- : [Hoboken, NJ] : Wiley
Original Publication: New York, NY : Hindawi Pub. Co.

Hemangioma*/drug therapy ; Propranolol*; Humans ; Lip ; Retrospective Studies ; Sclerotherapy

Objective: To analyze the therapeutic effect of oral propranolol combined with sclerotherapy of lauromacrogol and triamcinolone acetonide in the treatment of lip infantile hemangiomas (IHs).
Methods: We recorded the demographic characteristics and lesions of 56 patients with lip IHs. The efficacy was evaluated by Achauer grade and VAS score in this study. Nonparametric test and Spearman correlation analysis were used to identify factors that might affect the curative effect of patients, and multivariate logistic regression analysis was used to further analyze the factors that affect the prognosis of patients with lip IH.
Results: All 56 patients improved without serious complications after treatment. Univariate analysis showed that the age of the patients at the time of treatment initiation, the layer, classification, and volume of IH may influence the course and outcome of treatment. The logistic regression analysis further showed that the frequency of topical sclerotherapy was affected by the age of the months at the time of treatment initiation. The final efficacy evaluation was influenced by the age at the beginning of treatment and the layer of IH.
Conclusion: Oral propranolol combined with local sclerotherapy is a safe and effective method for treating lip IH. After combination therapy, the therapeutic effect of hemangiomas located in the mucosa and submucosa is better than those located in the skin and superficial subcutaneous fascia. Patients who were younger at treatment initiation received less frequencies of topical sclerotherapy and had better therapeutic effect.
Competing Interests: The authors declare that there are no conflicts of interest with respect to the publication of this paper.
(Copyright © 2022 Jiaqi Ling et al.)

Dermatol Surg. 2019 Oct;45(10):1253-1259. (PMID: 30882500)
Int J Mol Med. 2017 Mar;39(3):757-763. (PMID: 28112362)
Int J Clin Exp Med. 2015 Jul 15;8(7):10865-74. (PMID: 26379880)
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):2135-2139. (PMID: 32118308)
N Engl J Med. 2008 Jun 12;358(24):2649-51. (PMID: 18550886)
Head Neck. 2021 May;43(5):1553-1562. (PMID: 33539620)
J Oral Maxillofac Surg. 2020 Mar;78(3):446-454. (PMID: 31628904)
Pediatr Dermatol. 2013 Mar-Apr;30(2):182-91. (PMID: 23405852)
J Dermatol. 2019 Sep;46(9):770-776. (PMID: 31270853)
Pediatrics. 2016 Apr;137(4):. (PMID: 26952504)
Pediatr Blood Cancer. 2015 Aug;62(8):1414-20. (PMID: 25728347)
J Am Acad Dermatol. 2017 Feb;76(2):356-358. (PMID: 28089002)
Lancet. 2017 Jul 1;390(10089):85-94. (PMID: 28089471)
Plast Reconstr Surg Glob Open. 2019 Jun 19;7(6):e2308. (PMID: 31624693)
Dermatol Surg. 2010 Dec;36(12):2030-6. (PMID: 21040124)
Plast Reconstr Surg. 1997 Apr;99(5):1301-8. (PMID: 9105356)
Pediatr Int. 2016 Nov;58(11):1130-1135. (PMID: 26991797)
Exp Ther Med. 2018 Jun;15(6):4677-4682. (PMID: 29805486)
Br J Dermatol. 2014 Nov;171(5):1129-37. (PMID: 24720697)
Dermatol Surg. 2001 Jan;27(1):58-60. (PMID: 11231246)
J Drugs Dermatol. 2020 Dec 1;19(12):1156-1165. (PMID: 33346523)
Dermatol Ther. 2021 May;34(3):e14936. (PMID: 33704861)

9Y8NXQ24VQ (Propranolol)

Date Created: 20220804 Date Completed: 20220805 Latest Revision: 20220805

20250114

PMC9343181

10.1155/2022/6010458

35924268